Privacy settings

Utilizziamo cookies tecnici, necessari per il corretto funzionamento del sito, cookies statistici e cookies di marketing (inclusi cookies di terze parti), al fine di mostrarti offerte e pubblicità basate sui tuoi gusti e preferenze. Per maggiori informazioni puoi consultare la nostra Privacy Policy. I cookies statistici e i cookies di marketing (inclusi cookies di terze parti) sono utilizzati esclusivamente con il tuo consenso. Cliccando “Seleziona tutto e acconsenti” consenti il trattamento dei cookies statistici e di marketing (inclusi cookies di terze parti).

Cliccando “Rifiuta tutto”, rimarranno attive le impostazioni di default del sito (ossia verranno utilizzati esclusivamente cookie tecnici necessari per la navigazione).

Per personalizzare le tue impostazioni privacy, seleziona le tue preferenze tra le caselle qui sotto e clicca “Applica la selezione”. Ti ricordiamo per puoi modificare le tue impostazioni privacy in qualsiasi momento e disattivare i cookies, seguendo le istruzioni riportate nella Privacy Policy.

Deny all Show preferences Select all and accept
IMA is loading

Continuous Manufacturing to believe in.

Continuous Manufacturing underpins the improvement of pharmaceutical products in terms of potency, effectiveness and safety by means of accurate process control.

IMA’s way to Continuous Manufacturing

IMA Active is now ready for the paradigm shift in pharmaceutical manufacturing and taking the lead in the future of pharmaceutical technologies for OSD forms.

IMA Active’s belief in and knowledge of Continuous Manufacturing have grown stronger thanks to intensive R&D work carried out on two fronts.

CONTINUOUS FLOW OF BENEFITS


Quality

  • QbD approach bringing reduced time for quality control and test release.
  • Reduced risk of human errors due to a high level of automation.


Flexibility

  • Batch size and production volumes are defined by runtime. No more constraints due to equipment size.
  • Flexibility in process flow thanks to modularity of the CM operations.
  • CM unit operations are compact, designed with standard connections and minimum utilities, conceived for easy and quick installation to replicate in any manufacturing site worldwide with a short startup time.


Sustainability

  • Reduced plant footprint which means smaller equipment, no more need of work-in-process inventory, less personnel, with consequent space and energy savings.
  • Lower environmental impact through reduced utility consumption.
  • Reduced process surface to clean: less water consumption.
  • Less risk of drug shortage thanks to reduced time to market.


Costs

  • Important contribution for reducing costs includes smaller equipment and fewer manufacturing steps, with consequent saving for installation, validation and maintenance. In addition, rapid development, improved yields, less personnel achieve overall estimated cost reduction range from 30% to 50%, with impact on drugs affordability as well.


Safety

  • Patient safety is ensured by adoption of QbD and PAT (Process Analytical Technologies). Minimum risk to fall OOS (Out of Specifications).
  • Operator safety provided by lower risk of exposure means reduction of PPE.
  • Operators are better protected since product handling, process space and air displacement are significantly reduced.


Efficiency

  • Shorter time to market due to quicker product and process development, minimization of process scale-up.
  • Significant increase in productivity and improvement of OEE generated by:
    – Faster production time, also by minimizing product handling.
    – Reduction of waste and losses.
    – Quicker changeover due to minimum downtime.

THE CONTINUOUS SCENARIO

Based on more than 50 years’ process experience, IMA Active would like to involve you and rapidly illustrate the benefits of continuous processing. IMA Active contributes to making Continuous Manufacturing available for all and not just for a small elite of pharmaceutical manufacturers.

keyboard_arrow_left keyboard_arrow_right
  • Continuous direct compression
    Continuous direct compression
  • CDC with continuous coating
    CDC with continuous coating
  • CONTINUOUS DIRECT ENCAPSULATION
    CONTINUOUS DIRECT ENCAPSULATION

CDC is a very lean, efficient and flexible tablet-manufacturing technology that, in combination with PAT, allows easy adoption of a QbD approach.

CDC provides excellent operation performance; the system is designed to achieve a state of control very quickly and avoid any waste during startup and shutdown phases.

Continuous coating is a further manufacturing step that can be considered either straight inline or as a separate and subsequent step with regard to CDC. 

CROMA continuous coater is IMA Active’s novel technology for a fast and truly continuous process. Designed to be modular to manage a range of tablets throughput and a range of coating weight gain.

All the benefits of Continuous Manufacturing are gained by reducing the overall complexity of the product lifecycle and by decreasing the number of process variables.

Hardshell capsules are the preferred choice for packing a simple blend of powders with no other intermediate steps.

Academy

IMA Active has been cultivating its own knowledge and is ready to welcome the demand for innovation, working together with companies and stakeholders to design the future of pharmaceutical manufacturing.

From our event Can't Stop the future
Spotlight on Continuous Manufacturing in Oral Solid Dosage forms.

keyboard_arrow_left keyboard_arrow_right
play_circle_outline

Continuous Manufacturing: state of the art, challenges, and future prospects

Bernhardt L. Trout is Professor of Chemical Engineering at MIT and Director of Novartis-MIT Center for Continuous Manufacturing. His research focuses on the development of advanced manufacturing processes and rational tools for formulation and product design.

play_circle_outline

Global regulatory implementation on Continuous Manufacturing

Moheb M. Nasr managed the CDER Pharmaceutical Analysis Program at the US FDA for four years and had the lead of the CDER/FDA CMC Regulatory Program for more than eight years. He also worked for GSK as VP Global CMC Strategy. In 2018 he started his own consultancy business.

play_circle_outline

IMA’s way from batch to continuous

Guia Bertuzzi is Product Manager at IMA Active division since 2005. She has been working in mixing, granulation and powders handling systems for more than 20 years. She is expert in pharmaceutical engineering and process for Active Pharmaceutical Ingredients and Oral Solid Dosage forms.

play_circle_outline

Dynamic process models for continuous encapsulation processes

Keirnan LaMarche is Senior Principal Scientist at Patheon. He is an expert in solid dosage form design, continuous manufacturing, and he received his PhD in chemical Engineering from Rutgers University in 2008. He gained 10 years of experience in solid dosage form development at Bristol-Myers Squibb.

play_circle_outline

Making the switch from batch to Continuous Manufacturing: an industrial perspective

Giustino Di Pretoro is Associate Director at Janssen Pharmaceutica, a Johnson & Johnson Company. He is a subject matter expert and drug product development lead for Continuous Manufacturing, and coordinator for a series of academic collaborations within the field of continuous.

play_circle_outline

How to implement and validate Continuous Manufacturing of direct compression tablets: challenges and opportunities

Frank Streil is Director Technical and Scientific Affairs at Teva/RATIOPHARM. His main interests and experience are in the field of process development and validation as well as in new technologies, PAT and Continuous Manufacturing.

play_circle_outline

Control strategies for Continuous Manufacturing

Alan Johnston is Senior Life Sciences Consultant at Emerson’s Global consultancy team. He has spent a majority of his career in the Life Sciences industry with a broad range of technical and business experience across production, automation and digitalization including Primary, Secondary and Vaccine manufacture. He has previously held senior technical roles at Siemens, Novartis Vaccines and GSK.